Your browser doesn't support javascript.
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli, F; Giannarelli, D; Fabbri, A; Silvestri, M A; Berrios, J R Giron; Virtuoso, A; Marrucci, E; Schirripa, M; Mazzotta, M; Onorato, A; Panichi, V; Topini, G; Pessina, G; Natoni, F; Signorelli, C; Chilelli, M G; Primi, F; Ruggeri, E M.
  • Nelli F; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy. Electronic address: fabrizio.nelli@asl.vt.it.
  • Giannarelli D; Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • Fabbri A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Silvestri MA; Departments of Oncology and Hematology, Microbiology and Virology Unit, Viterbo, Italy.
  • Berrios JRG; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Virtuoso A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Marrucci E; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Schirripa M; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Mazzotta M; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Onorato A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Panichi V; Departments of Oncology and Hematology, Microbiology and Virology Unit, Viterbo, Italy.
  • Topini G; Departments of Oncology and Hematology, Microbiology and Virology Unit, Viterbo, Italy.
  • Pessina G; Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.
  • Natoni F; Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.
  • Signorelli C; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Chilelli MG; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Primi F; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Ruggeri EM; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
Ann Oncol ; 33(7): 740-742, 2022 07.
Article in English | MEDLINE | ID: covidwho-1777966
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Ann Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Ann Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article